BC Week In Review | Oct 5, 2018
Financial News

New IPO filings include NGM, Arog, Gamida

Three biotechs filed late Sept. 28 to go public on NASDAQ, adding new companies to a 2018 class of IPOs that could surpass 2015's record for funds raised. The group includes NGM Biopharmaceuticals Inc. (South...
BC Innovations | Nov 10, 2017
Product R&D

Blueprint gets the GIST

Blueprint is positioning its kinase inhibitor BLU-285 to take a dominant position in gastrointestinal tumors, with preclinical and Phase I data showing the compound inhibits not only mutant forms of c-Kit and PDGFRA that underlie...
BC Innovations | Oct 10, 2017
Distillery Therapeutics


INDICATION: Acute myelogenous leukemia (AML) In vitro , cell culture and mouse studies identified two USP10 inhibitors that could help treat AML harboring internal tandem duplication (ITD) mutations in FLT3 . Screening of deubiquitinating enzyme (DUB) inhibitors...
BC Week In Review | Nov 18, 2016
Clinical News

Crenolanib regulatory update

Arog said FDA granted Fast Track designation to crenolanib besylate to treat unresectable or metastatic gastrointestinal tumors (GIST) harboring the platelet-derived growth factor receptor alpha (PDGFRA) D824V mutation. Crenolanib besylate is in Phase III testing...
BC Week In Review | May 31, 2010
Company News

Arog, Pfizer deal

Pfizer granted newco Arog exclusive, worldwide rights to small molecule platelet derived growth factor receptor (PDGFR) inhibitors plarotinib ( CP-868596 ) and CP-673451. Arog renamed the compounds ARO-002 and ARO-001, respectively. Arog plans to start a clinical...
Items per page:
1 - 5 of 5